U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H8O4
Molecular Weight 180.1578
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ASPIRIN

SMILES

CC(=O)Oc1ccccc1C(=O)O

InChI

InChIKey=BSYNRYMUTXBXSQ-UHFFFAOYSA-N
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

HIDE SMILES / InChI

Molecular Formula C9H8O4
Molecular Weight 180.1578
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

CNS Activity

Curator's Comment:: The penetration of the blood-brain barrier was studied in animals.

Originator

Curator's Comment:: Felix Hoffmann discovered aspirin when working for Friedrich Bayer & Co. # Bayer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P23219|||Q5T7T7
Gene ID: 5742.0
Gene Symbol: PTGS1
Target Organism: Homo sapiens (Human)
1.2 µM [IC50]
Target ID: P35354
Gene ID: 5743.0
Gene Symbol: PTGS2
Target Organism: Homo sapiens (Human)
5.2 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SYNALGOS-DC

Approved Use

SYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Launch Date

-3.62620813E11
Primary
FIORINAL

Approved Use

FIORINAL is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fiorinal in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

Launch Date

2.00016003E11
Preventing
DURLAZA

Approved Use

DURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack.

Launch Date

1.44132486E12
Preventing
AGGRENOX

Approved Use

AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

Launch Date

9.4322878E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
54.25 mg/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.84 mg/L
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10.31 mg × h/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5.12 mg × h/L
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.322 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.422 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ASPIRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
68%
ASPIRIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
yes [Km 1242 uM]
yes [Km 2337 uM]
yes [Km 278.6 uM]
yes [Km 40.7 uM]
yes [Km 683.1 uM]
yes [Km 698.2 uM]
yes [Km 94.2 uM]
yes
yes
yes
yes
yes
yes
yes
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Letter: Aspirin sensitivity: other drugs.
1975 Feb
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.
2000 Aug
Pharmacotherapies for cocaine dependence.
2000 Dec
The discovery of aspirin: a reappraisal.
2000 Dec 23-30
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen.
2000 Dec 8
[Cholestatic hepatitis as a rare side effect of therapy with ticlopidine].
2000 Jul
Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough.
2000 Jul
An uncommon case of fluid retention simulating a congestive heart failure after aspirin consumption.
2000 Jul
Symptomatic secondary hemorrhagic transformation of ischemic Wallenberg's syndrome.
2000 Jun
Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates.
2000 Jun 16
Aspirin-associated intracerebral hemorrhage: clinical and radiologic features.
2000 Jun 27
[Aspirin-induced angioedema of the nape of the neck with naproxen cross-reaction: a case report].
2000 May
Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema.
2000 Sep
The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation.
2000 Sep
Aspirin induces apoptosis through mitochondrial cytochrome c release.
2000 Sep 1
Novel platelet inhibitors.
2001
Collagen as a model system to investigate the use of aspirin as an inhibitor of protein glycation and crosslinking.
2001 Apr
Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study.
2001 Feb
Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions.
2001 Feb
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
2001 Feb
Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people.
2001 Feb
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia.
2001 Feb 2
Platelet-active drugs : the relationships among dose, effectiveness, and side effects.
2001 Jan
Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA.
2001 Jan
Multiple endothelial injury in epicardial coronary artery induces downstream microvascular spasm as well as remodeling partly via thromboxane A2.
2001 Jan
Lp(a) lipoprotein--an independent risk factor for coronary heart disease after menopause.
2001 Jan
The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation.
2001 Jan
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols.
2001 Jan
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis.
2001 Jan
Low-dose aspirin therapy and periodontal attachment loss in ex- and non-smokers.
2001 Jan
Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses.
2001 Jan
[Leukocytoclastic vasculitis associated with ticlopidine].
2001 Jan
Antithrombotic therapy in cardiac stent patients.
2001 Jan
Anticoagulation and heart failure.
2001 Jan
Is optimal antithrombotic therapy after myocardial infarction well defined?
2001 Jan
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia.
2001 Jan
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo.
2001 Jan
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
2001 Jan
Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin.
2001 Jan
Another reason for taking aspirin.
2001 Jan
Hypothesized treatment for migraines using low doses of tryptophan, niacin, calcium, caffeine, and acetylsalicylic acid.
2001 Jan
Increased platelet reactivity and significant changes in coagulation markers after cavopulmonary connection.
2001 Jan
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Blood donations and risk of coronary heart disease in men.
2001 Jan 2
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
2001 Jan 2
Authors' reply on aspirin for primary prevention.
2001 Jan 20
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
2001 Jan 23
Pharmacological properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-.
2001 Jan 5
Drug Points: tachycardia associated with moxifloxacin.
2001 Jan 6
The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa.
2001 Mar 9
Patents

Sample Use Guides

In Vivo Use Guide
Severe pain: Initiate treatment with two capsules (1 capsule contains 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine) orally every 4 hours as needed for pain. Headache: One or 2 capsules (1 capsule contains 50 mg butalbital, 325 mg aspirin and 40 mg caffeine) every 4 hours. Total daily dose should not exceed 6 capsules. Prevention of stoke and heart attacks: the recommended dose is one capsule of aspirin (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Prevention of stroke (in combination with dipyridamole): the recommended dose is one capsule (200 mg dipyridamole and 25 mg aspirin) given orally twice daily.
Route of Administration: Enteral
In Vitro Use Guide
Human platelet-rich plasma was incubated with various aspirin concentrations (10, 20, 50, 100, 200, 300, 400, 500 uM) at 37C for up to 4.5 h. Platelet aggregation and thromboxane generation were measured. Inhibition of platelet aggregation and thromboxane formation by 10 uM aspirin was maximal by 90 min. There was progressive inhibition by 3 uM aspirin during incubation for 270 min. By the end of this time there was also significant inhibition by 1 uM aspirin.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:12:33 UTC 2021
Edited
by admin
on Fri Jun 25 21:12:33 UTC 2021
Record UNII
R16CO5Y76E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ASPIRIN
HSDB   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
ASPIRIN COMPONENT OF VICOPRIN
Common Name English
CLOPIDOGREL/ACETYLSALICYLIC ACID COMPONENT ASPIRIN
Brand Name English
DUOCOVER COMPONENT ASPIRIN
Brand Name English
ASPIRIN COMPONENT OF MICRAININ
Common Name English
ACETYL SALICYLATE
Systematic Name English
ASPIRIN COMPONENT OF EQUAGESIC
Common Name English
2-ACETYLOXYBENZOIC ACID
Systematic Name English
ASPIRIN [ORANGE BOOK]
Common Name English
ASPIRIN COMPONENT OF AGGRENOX
Common Name English
BAY1019036
Code English
INVAGESIC FORTE COMPONENT ASPIRIN
Common Name English
DUOPLAVIN COMPONENT ASPIRIN
Brand Name English
ASA
Common Name English
ASPIRIN COMPONENT OF LANORINAL
Common Name English
ACETYLSALICYLIC ACID [WHO-DD]
Common Name English
ACETYLSALICYLIC ACID [EMA EPAR]
Common Name English
NSC-27223
Code English
AGGRENOX COMPONENT ASPIRIN
Common Name English
CODOXY COMPONENT ASPIRIN
Common Name English
MEASURIN
Brand Name English
ASPIRIN COMPONENT OF ROXIPRIN
Common Name English
ROXIPRIN COMPONENT ASPIRIN
Common Name English
ACETYLSALICYLIC ACID [GREEN BOOK]
Common Name English
ACETYLSALICYLIC ACID (WHO-IP)
Common Name English
NORGESIC COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF ROBAXISAL
Common Name English
ASPIRIN [MART.]
Common Name English
ASPIRIN COMPONENT OF YOSPRALA
Brand Name English
ASPIRIN COMPONENT OF NORGESIC
Common Name English
MEPRO-ASPIRIN COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF CARISOPRODOL COMPOUND
Common Name English
ASPIRIN [VANDF]
Common Name English
ORPHENGESIC COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF SOMA COMPOUND
Common Name English
PRAVIGARD PAC COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF AXOTAL
Common Name English
DARVON COMPOUND COMPONENT ASPIRIN
Common Name English
ACIDUM ACETYLSALICYLICUM (WHO-IP)
Common Name English
AXOTAL COMPONENT ASPIRIN
Common Name English
INVAGESIC COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF EXCEDRIN
Common Name English
ASPIRIN COMPONENT OF INVAGESIC
Common Name English
MICRAININ COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF TALWIN COMPOUND
Common Name English
LANORINAL COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF INVAGESIC FORTE
Common Name English
SYNALGOS-DC COMPONENT ASPIRIN
Common Name English
ASPIRIN [JAN]
Common Name English
ASPIRIN COMPONENT OF MEPRO-ASPIRIN
Common Name English
ASPIRIN [USP-RS]
Common Name English
NSC-406186
Code English
BENZOIC ACID, 2-(ACETYLOXY)-
Common Name English
ASPIRIN COMPONENT OF PRAVIGARD PAC
Common Name English
FIORINAL COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF AZDONE
Common Name English
ACIDUM ACETYLSALICYLICUM
Common Name English
ASPIRIN COMPONENT OF SYNALGOS-DC
Common Name English
ASPIRIN COMPONENT OF PERCODAN
Common Name English
CARISOPRODOL COMPOUND COMPONENT ASPIRIN
Common Name English
SALICYLIC ACID ACETATE
Systematic Name English
Q-GESIC COMPONENT ASPIRIN
Common Name English
PERCODAN-DEMI COMPONENT ASPIRIN
Common Name English
VICOPRIN COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF DUOPLAVIN
Brand Name English
ASPIRIN COMPONENT OF DUOCOVER
Brand Name English
AZDONE COMPONENT ASPIRIN
Common Name English
ACETYLSALICYLIC ACID [EP MONOGRAPH]
Common Name English
EXCEDRIN COMPONENT ASPIRIN
Common Name English
SOMA COMPOUND COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF ORPHENGESIC
Common Name English
ACETYLSALICYLICUM ACIDUM [HPUS]
Common Name English
ASPIRIN [HSDB]
Common Name English
ROBAXISAL COMPONENT ASPIRIN
Common Name English
ACETYLSALICYLIC ACID
EMA EPAR   EP   GREEN BOOK   INCI   WHO-DD  
INCI  
Official Name English
2-(ACETYLOXY)BENZOIC ACID
Systematic Name English
EQUAGESIC COMPONENT ASPIRIN
Common Name English
PERCODAN COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF CODOXY
Common Name English
ASPIRIN COMPONENT OF PERCODAN-DEMI
Common Name English
ASPIRIN [USP]
Common Name English
ASPIRIN [MI]
Common Name English
YOSPRALA COMPONENT ASPIRIN
Brand Name English
ORPHENGESIC FORTE COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF Q-GESIC
Common Name English
ACETYLSALICYLICUM ACIDUM
HPUS  
Common Name English
ASPIRIN COMPONENT OF FIORINAL
Common Name English
ASPIRIN COMPONENT OF ORPHENGESIC FORTE
Common Name English
ASPIRIN COMPONENT OF CLOPIDOGREL/ACETYLSALICYLIC ACID
Brand Name English
ACETYLSALICYLIC ACID [INCI]
Common Name English
DURLAZA
Brand Name English
TALWIN COMPOUND COMPONENT ASPIRIN
Common Name English
ASPIRIN COMPONENT OF DARVON COMPOUND
Common Name English
Classification Tree Code System Code
WHO-ATC C07FX02
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
CFR 21 CFR 343.13
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
CFR 21 CFR 343.12
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QN02BA51
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC C10BX01
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QB01AC56
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
LIVERTOX 68
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC C10BX05
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC A01AD05
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QM01BA03
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
EMA ASSESSMENT REPORTS DUOCOVER (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC M01BA03
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
FDA ORPHAN DRUG 724719
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC C10BX04
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
EMA ASSESSMENT REPORTS CLOPIDOGREL/ACETYLSALICYLIC ACID (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
EMA ASSESSMENT REPORTS CLOPIDOGREL/ACETYLSALICYCLIC ACID (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC N02AJ02
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
FDA ORPHAN DRUG 764120
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QN02BA71
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QB01AC06
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
EMA ASSESSMENT REPORTS DUOPLAVIN (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QC10BX05
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
NDF-RT N0000008836
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
NDF-RT N0000000160
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
EMA ASSESSMENT REPORTS DUOPLAVIN (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 12.5
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
NDF-RT N0000008836
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC N02BA71
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC N02BA01
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
FDA ORPHAN DRUG 724619
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QC10BX02
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
FDA ORPHAN DRUG 607917
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC C10BX08
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
NDF-RT N0000175722
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
CFR 21 CFR 520.1409
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC B01AC08
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC B01AC56
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
EU-Orphan Drug EU/3/04/208
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC N02BA51
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC B01AC06
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC C10BX06
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC N02BA15
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QA01AD05
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC C10BX02
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC C10BX12
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
NDF-RT N0000175721
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
NDF-RT N0000175578
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC N02AJ07
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QC10BX01
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC N02AJ18
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
EPA PESTICIDE CODE 129061
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 7.1
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 2.1
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
CFR 21 CFR 341.40
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC C07FX03
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC C07FX04
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QN02BA01
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
EMA ASSESSMENT REPORTS DUOCOVER (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-VATC QC10BX04
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
WHO-ATC N02BA65
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
Code System Code Type Description
DRUG BANK
DB00945
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
MESH
D001241
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-064-1
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
PUBCHEM
2244
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
NCI_THESAURUS
C287
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
FDA UNII
R16CO5Y76E
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
HSDB
652
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
USP_CATALOG
1044006
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY USP-RS
RXCUI
1191
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
CAS
50-78-2
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
DRUG CENTRAL
74
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
RXCUI
91101
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
ALTERNATIVE
EVMPD
SUB12730MIG
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
MERCK INDEX
M2111
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY Merck Index
IUPHAR
4139
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
WIKIPEDIA
ASPIRIN
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ASPIRIN
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY Description: Colourless crystals or a white, crystalline powder; odourless or almost odourless. Solubility: Soluble in about 300 parts of water; freely soluble in ethanol (~750 g/l) TS; soluble in ether R. Category: Analgesic; antipyretic. Storage: Acetylsalicylic acid should be kept in a tightly closed container, protected from light. Additional information: Even in the absence of light, Acetylsalicylic acid is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Acetylsalicylic acid contains not less than 99.0% and not more than 100.5% of C9H8O4, calculated with reference to the dried substance.
LACTMED
Aspirin
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
ChEMBL
CHEMBL25
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
EPA CompTox
50-78-2
Created by admin on Fri Jun 25 21:12:34 UTC 2021 , Edited by admin on Fri Jun 25 21:12:34 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE ACTIVE -> PARENT
MINOR
URINE
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
IDENTIFIED AS IMPURITY E Limits: impurity E: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)Herbal Medicines 4th ED 2103
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IDENTIFIED AS IMPURITY A Limits: impurity A: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
IMPURITY -> PARENT
IDENTIFIED AS IMPURITY C Limits: impurity C: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Limits: impurity B: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IDENTIFIED AS IMPURITY F Limits: impurity F: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
ASSAY (COLORIMETRIC)
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
Limits: impurity A: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IDENTIFIED AS IMPURITY D Limits: impurity D: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)Herbal Medicines 4th ED 2103
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IDENTIFIED AS IMPURITY E Limits: impurity E: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
IMPURITY -> PARENT
IDENTIFIED AS IMPURITY B Limits: impurity B: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
Related Record Type Details
ACTIVE MOIETY